The trial is taking place at:
G

Geisinger Clinic | Geisinger Danville - Anesthesiology

Veeva-enabled site

DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

R

Rhythm Pharmaceuticals

Status and phase

Active, not recruiting
Phase 2

Conditions

Genetic Obesity

Treatments

Drug: Setmelanotide
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04963231
RM-493-034

Details and patient eligibility

About

A 2-stage (open-label run-in, followed by randomized, double-blind, placebo-controlled withdrawal) trial of setmelanotide in patients with obesity and specific gene defects variants in the melanocortin-4 receptor (MC4R) pathway.

Enrollment

150 estimated patients

Sex

All

Ages

6 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must have a pre-identified genetic variant in an established MC4R pathway gene that contributes to obesity
  • Age 6 to 65 years, inclusive
  • Obesity, defined as BMI ≥40 kg/m2 for patients≥18 years of age or BMI ≥97th percentile for age and gender for patients 6 up to 17 years of age
  • Study participant and/or parent or guardian is able to understand all study procedures and provide consent/assent
  • Use of highly effective contraception
  • Symptoms or behaviors of hyperphagia

Exclusion criteria

  • Patients with the following genetic variants: biallelic Bardet-Biedl Syndrome (BBS); biallelic Alström Syndrome 1 (ALMS1); homozygous, heterozygous, or compound heterozygous variants in MC4R, POMC, PCSK1, LEPR, nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator-1 [SRC1]) or SRC homology 2 B adapter protein 1 (SH2B1) genes as well as 16p11.2 chromosomal deletions that include the SH2B1 gene
  • Recent intensive diet and/or exercise regimen with or without the use of weight loss agents including herbal medications that has resulted in weight loss >2% within previous 3 months
  • Bariatric surgery within the previous 6 months.
  • Documented diagnosis of schizophrenia, bipolar disorder, personality disorder, major depressive disorder, or other psychiatric disorder(s)
  • Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) or Patient Health Questionnaire 9 (PHQ 9) score of ≥15 during Screening, any suicide attempt in patient's lifetime years, or any suicidal behavior in the last month.
  • Current, clinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study
  • Has significant features of (or meets the diagnostic criteria for) a genetic syndrome that is associated with obesity
  • HbA1C >10.0% at Screening
  • History of significant liver disease
  • Glomerular filtration rate (GFR) <30 mL/min at Screening
  • History or close family history of melanoma or patient history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Patients previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • Females who are breastfeeding or nursing

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Triple Blind

150 participants in 2 patient groups, including a placebo group

Setmelanotide
Experimental group
Description:
Patients with specific gene variants in the MC4R pathway on setmelanotide
Treatment:
Drug: Setmelanotide
Placebo
Placebo Comparator group
Description:
Patients with specific gene variants in the MC4R pathway on placebo
Treatment:
Drug: Placebo

Trial contacts and locations

36

Loading...

Central trial contact

Physician Inquiry: Clinical Trials; Rhythm Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems